BACKGROUND: This study aimed to establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab, and to estimate the efficacy (response rate and progression free survival [PFS]) and safety of combination therapy with carboplatin, bortezomib, and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: Patients were assigned to three dose levels of weekly bortezomib with the fixed standard doses of carboplatin AUC 6 and bevacizumab (15 mg/kg) every 3 weeks using a standard phase-I design. Bortezomib doses were 1.3 mg/m, 1.6 mg/m, and 1.8 mg/m weekly on day 1 and day 8 of every 3-week cycle. A maximum of six cycles was administered. Patients with complete, partial response or stable disease were continued on single-agent bevacizumab (15 mg/kg every 3 weeks) as maintenance therapy. In phase II, either level III or MTD was administered to evaluate the efficacy and safety of the combination in first-line treatment of advanced NSCLC. RESULTS:Sixteen patients were enrolled (three, four, and nine patients in dose level I, II, and III, respectively). There was no predefined dose limiting toxicity in cycle 1 in all 16 patients. The recommended phase-II dose is bortezomib 1.8 mg/m weekly on day 1 and day 8 in combination with carboplatin AUC 6 and bevacizumab 15 mg/kg on every 21-day cycle. Totally 9 patients were treated at the recommended phase-II dose level. The most common treatment related grade-3/4 toxicities during the subsequent cycles were thrombocytopenia (58%), lymphopenia (25%), neutropenia (12%), and diarrhea (25%). The grade-1/2 neuropathy was seen in 7 out of 16 patients (44%). The response rate, PFS, and overall survival in all patients were 37.5% (95%CI 13.8%-61.2%), 5.0 months (95%CI: 3.1-8.4), 9.9 months (95% CI: 8.2-14.1), and among the 9 patients in phase-II portion are 44% (95%CI 15.3%-77.3%), 5.5 months (95%CI: 3.1-2.2) and 10.9 months (95%CI: 8.0-14.1). CONCLUSION: The recommended phase-II dose for this combination is: carboplatin AUC 6, bevacizumab 15 mg/kg on day 1 and bortezomib 1.8 mg/m on day 1 and day 8 on every 21-day cycle. The regimen was very well tolerated with interesting clinical activity in first-line treatment of NSCLC.
RCT Entities:
BACKGROUND: This study aimed to establish the maximum tolerated dose (MTD) of weekly bortezomib in combination with fixed standard doses of carboplatin and bevacizumab, and to estimate the efficacy (response rate and progression free survival [PFS]) and safety of combination therapy with carboplatin, bortezomib, and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Patients were assigned to three dose levels of weekly bortezomib with the fixed standard doses of carboplatin AUC 6 and bevacizumab (15 mg/kg) every 3 weeks using a standard phase-I design. Bortezomib doses were 1.3 mg/m, 1.6 mg/m, and 1.8 mg/m weekly on day 1 and day 8 of every 3-week cycle. A maximum of six cycles was administered. Patients with complete, partial response or stable disease were continued on single-agent bevacizumab (15 mg/kg every 3 weeks) as maintenance therapy. In phase II, either level III or MTD was administered to evaluate the efficacy and safety of the combination in first-line treatment of advanced NSCLC. RESULTS: Sixteen patients were enrolled (three, four, and nine patients in dose level I, II, and III, respectively). There was no predefined dose limiting toxicity in cycle 1 in all 16 patients. The recommended phase-II dose is bortezomib 1.8 mg/m weekly on day 1 and day 8 in combination with carboplatin AUC 6 and bevacizumab 15 mg/kg on every 21-day cycle. Totally 9 patients were treated at the recommended phase-II dose level. The most common treatment related grade-3/4 toxicities during the subsequent cycles were thrombocytopenia (58%), lymphopenia (25%), neutropenia (12%), and diarrhea (25%). The grade-1/2 neuropathy was seen in 7 out of 16 patients (44%). The response rate, PFS, and overall survival in all patients were 37.5% (95%CI 13.8%-61.2%), 5.0 months (95%CI: 3.1-8.4), 9.9 months (95% CI: 8.2-14.1), and among the 9 patients in phase-II portion are 44% (95%CI 15.3%-77.3%), 5.5 months (95%CI: 3.1-2.2) and 10.9 months (95%CI: 8.0-14.1). CONCLUSION: The recommended phase-II dose for this combination is: carboplatin AUC 6, bevacizumab 15 mg/kg on day 1 and bortezomib 1.8 mg/m on day 1 and day 8 on every 21-day cycle. The regimen was very well tolerated with interesting clinical activity in first-line treatment of NSCLC.
Authors: Primo N Lara; Jeff Longmate; Karen Reckamp; Barbara Gitlitz; Athanassios Argiris; Suresh Ramalingam; Chandra P Belani; Philip C Mack; Derick H M Lau; Mariana Koczywas; John J Wright; Frances A Shepherd; Natasha Leighl; David R Gandara Journal: Clin Lung Cancer Date: 2011-01 Impact factor: 4.785
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Carol Aghajanian; Steven Soignet; Don S Dizon; Christine S Pien; Julian Adams; Peter J Elliott; Paul Sabbatini; Vincent Miller; Martee L Hensley; Sandra Pezzulli; Christina Canales; Adil Daud; David R Spriggs Journal: Clin Cancer Res Date: 2002-08 Impact factor: 12.531
Authors: Giorgio V Scagliotti; Paul Germonpré; Leon Bosquée; Johan Vansteenkiste; R Gervais; David Planchard; Martin Reck; Filippo De Marinis; Jin Soo Lee; Keunchil Park; Bonne Biesma; Steven Gans; R Ramlau; Aleusandra Szczesna; A Makhson; G Manikhas; Bruno Morgan; Y Zhu; Kai C Chan; Joachim von Pawel Journal: Lung Cancer Date: 2009-08-18 Impact factor: 5.705
Authors: Thomas J Lynch; David Fenton; Vera Hirsh; David Bodkin; Edward L Middleman; Alberto Chiappori; Balazs Halmos; Reyna Favis; Hua Liu; William L Trepicchio; Omar Eton; Frances A Shepherd Journal: J Thorac Oncol Date: 2009-08 Impact factor: 15.609
Authors: Yi-He Ling; Leonard Liebes; Bruce Ng; Michael Buckley; Peter J Elliott; Julian Adams; Jian-Dong Jiang; Franco M Muggia; Roman Perez-Soler Journal: Mol Cancer Ther Date: 2002-08 Impact factor: 6.261
Authors: Qiyuan Zhou; Jingbo Dai; Tianji Chen; Laura A Dada; Xu Zhang; Wei Zhang; Malcolm M DeCamp; Robert A Winn; Jacob I Sznajder; Guofei Zhou Journal: Cell Signal Date: 2017-06-24 Impact factor: 4.315
Authors: Kunal R Chaudhary; Connor J Kinslow; Haiying Cheng; Jose M Silva; Jiyang Yu; Tony J Wang; Tom K Hei; Balazs Halmos; Simon K Cheng Journal: Sci Rep Date: 2022-06-16 Impact factor: 4.996
Authors: Yujie Zhao; Nathan R Foster; Jeffrey P Meyers; Sachdev P Thomas; Donald W Northfelt; Kendrith M Rowland; Bassam I Mattar; David B Johnson; Julian R Molina; Sumithra J Mandrekar; Steven E Schild; James D Bearden; Marie-Christine Aubry; Alex A Adjei Journal: J Thorac Oncol Date: 2015-01 Impact factor: 15.609
Authors: Jonathan H Young; Michael Peyton; Hyun Seok Kim; Elizabeth McMillan; John D Minna; Michael A White; Edward M Marcotte Journal: Bioinformatics Date: 2016-01-10 Impact factor: 6.937
Authors: Xiaorong Sun; Ellen Ackerstaff; Fuqiu He; Ligang Xing; Hung Tsung Hsiao; Jason A Koutcher; C Clifton Ling; Gloria C Li Journal: Oncotarget Date: 2015-10-27